Published online Oct 26, 2018. doi: 10.4252/wjsc.v10.i10.138
Peer-review started: June 25, 2018
First decision: July 19, 2018
Revised: July 29, 2018
Accepted: August 26, 2018
Article in press: August 26, 2018
Published online: October 26, 2018
Decompensated liver cirrhosis greatly affects patients’ life quality and expectancy. However, the tumorigenicity of stem cells impedes them as a basis for regenerative medicine treatment.
This study evaluates the long-term efficacy and safety of autologous stem cell transplantation (SCT) for decompensated liver cirrhosis based on ten years of follow-up.
We aimed to compare the survival rate and incidence of hepatocellular carcinoma (HCC) in decompensated liver cirrhosis patients with and without SCT, so as to evaluate the long-term efficacy and safety of SCT.
Consecutive patients with decompensated liver cirrhosis were included and assigned into the SCT group and non-transplantation (non-SCT) group according to whether they received SCT treatment. Patients were followed up for ten years.
The incidence of HCC was higher in the SCT group than in the non-SCT group. After adjusting for other covariates, SCT and age were independently correlated with the development of HCC in this decompensated liver cirrhosis cohort.
Autologous SCT may fail to improve the long-term efficacy and increase the incidence of HCC for decompensated liver cirrhosis.
Close monitoring of HCC is strongly recommended in patients undergoing autologous SCT.